The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000848303p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
22/02/2026
Date registered
Help: Date registered
13/07/2026
Date last updated
Help: Date last updated
13/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
13/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Pain control after ACL reconstruction: comparing two nerve block techniques
Scientific title
Pain and opioid usage in hamstring tendon anterior cruciate ligament reconstruction with adductor canal block versus IPACK block: a single-centre randomised controlled trial
Additional trial identifiers [1] 316399 0
Nil known
Universal Trial Number (UTN)
Trial acronym
PHARAOH
Related trial records

Health condition
Health condition(s) studied:
Anterior cruciate ligament rupture requiring surgical reconstruction 340792 0
Postoperative pain following anterior cruciate ligament reconstruction 340795 0
Condition category
Condition code
Injuries and Accidents 336966 336966 0 0
Other injuries and accidents
Musculoskeletal 336967 336967 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Brief name: IPACK block plus local infiltration analgesia for postoperative analgesia following hamstring tendon anterior cruciate ligament reconstruction.
Description of intervention(s):
Participants allocated to the intervention group will receive an ultrasound-guided IPACK (Infiltration between the Popliteal Artery and Capsule of the Knee) block administered by a consultant anaesthetist experienced in ultrasound-guided regional anaesthesia.
Timing: Single administration intraoperatively, immediately following induction of general anaesthesia and prior to surgical incision.
Technique and dose: Under ultrasound guidance, a 20-gauge needle is inserted into the interspace between the popliteal artery and posterior capsule of the knee. Following negative aspiration, 20 mL of bupivacaine 0.25% is injected incrementally. Single dose; not repeated.
Co-intervention (standardised for both groups): All participants additionally receive local infiltration analgesia (LIA) — bupivacaine 0.5% 20 mL infiltrated into peri-articular tissues at surgical completion prior to wound closure, plus ketorolac 30 mg intravenously intraoperatively.
Standardised background analgesia (both groups): General anaesthesia, paracetamol 1 g four times daily (regular), oxycodone 5–10 mg orally every 4 hours as required, and intraoperative fentanyl titrated to haemodynamic response.
Adherence: All blocks are performed to a standardised protocol by consultant anaesthetists trained in ultrasound-guided regional anaesthesia. Anaesthetic records are reviewed post-procedure to confirm adherence to technique and dosing.
Intervention code [1] 333283 0
Treatment: Surgery
Intervention code [2] 333533 0
Treatment: Drugs
Description of the comparator or control
Comparator / control treatment:
Ultrasound-guided adductor canal block (ACB) combined with local infiltration analgesia (LIA), administered peri-operatively as part of standard care during anterior cruciate ligament reconstruction.

Timing (ACB): The adductor canal block will be administered intraoperatively immediately following induction of general anaesthesia and prior to surgical incision.

Technique and dose (ACB): Under ultrasound guidance, a 20-gauge needle will be inserted into the adductor canal adjacent to the femoral artery beneath the sartorius muscle. Following negative aspiration, 15 mL of 0.25% bupivacaine will be injected incrementally.

Provider: The block will be performed by consultant anaesthetists experienced in ultrasound-guided regional anaesthesia.

Local infiltration analgesia (LIA):

Timing (LIA): Local infiltration analgesia will be administered intraoperatively at the completion of the surgical procedure, prior to wound closure.

Technique and dose (LIA): 20 mL of 0.5% bupivacaine will be infiltrated into peri-articular tissues at the surgical site. In addition, 30 mg ketorolac (intravenous) will be administered intraoperatively as part of the multimodal analgesic regimen.
Control group
Active

Outcomes
Primary outcome [1] 344488 0
Postoperative opioid consumption
Timepoint [1] 344488 0
Postoperative days 1, 2, 3, and 7 following surgery.
Secondary outcome [1] 458020 0
Patient satisfaction with postoperative pain management
Timepoint [1] 458020 0
Postoperative day 7 following surgery.
Secondary outcome [2] 458021 0
Knee function
Timepoint [2] 458021 0
Postoperative weeks 2, 6, and 12.
Secondary outcome [3] 458022 0
Knee-related symptoms
Timepoint [3] 458022 0
Postoperative weeks 2, 6, and 12
Secondary outcome [4] 463912 0
Knee-related quality of life
Timepoint [4] 463912 0
2 weeks, 6 weeks, and 12 weeks postoperatively
Secondary outcome [5] 463913 0
Patient satisfaction with pain relief
Timepoint [5] 463913 0
7 days postoperatively

Eligibility
Key inclusion criteria
• Aged 16 to 75 years.
• American Society of Anaesthesiologists physical status grade I or II.
• Undergoing primary anterior cruciate ligament reconstruction using hamstring tendon autograft.
• Able to provide informed consent.
• Undergoing surgery at Hornsby Hospital.
Minimum age
16 Years
Maximum age
75 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Revision anterior cruciate ligament reconstruction.
• Known allergy or contraindication to local anaesthetics, opioids, or study medications.
• Chronic opioid use within the preceding 3 months.
• Coagulopathy or bleeding disorder.
• Severe hepatic or renal impairment.
• History of alcohol or substance use disorder.
• Inability to comply with study procedures or follow-up.
• Refusal or inability to provide informed consent.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation will be concealed using sequentially numbered, opaque, sealed envelopes prepared by an independent member of the research team not involved in recruitment, clinical care, or outcome assessment. Envelopes will be opened only after participant enrolment and completion of baseline eligibility checks.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A computer-generated randomisation sequence will be created using randomizer.org with a 1:1 allocation ratio between treatment groups. Randomisation will be performed in blocks of 25 to ensure balanced group sizes.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Continuous variables will be summarised using means and standard deviations or medians and interquartile ranges depending on distribution. Normality will be assessed using the Shapiro–Wilk test. Between-group comparisons will be performed using independent samples t-tests for normally distributed data or Mann–Whitney U tests for non-parametric data. Categorical variables will be analysed using chi-square or Fisher’s exact tests as appropriate. Statistical significance will be set at a two-sided p-value of 0.05. Analyses will be conducted using IBM SPSS Statistics software.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 29164 0
Hornsby Ku-ring-gai Hospital - Hornsby
Recruitment postcode(s) [1] 45479 0
2077 - Hornsby

Funding & Sponsors
Funding source category [1] 321011 0
Government body
Name [1] 321011 0
Northern Sydney Local Health District
Country [1] 321011 0
Australia
Primary sponsor type
Government body
Name
Northern Sydney Local Health District
Address
Country
Australia
Secondary sponsor category [1] 325260 0
None
Name [1] 325260 0
Address [1] 325260 0
Country [1] 325260 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 319543 0
Northern Sydney Local Health District Human Research Ethics Committee
Ethics committee address [1] 319543 0
Ethics committee country [1] 319543 0
Australia
Date submitted for ethics approval [1] 319543 0
27/02/2026
Approval date [1] 319543 0
Ethics approval number [1] 319543 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 147670 0
Dr Karan Sandhu
Address 147670 0
Hornsby Hospital, Palmerston Road, Hornsby, NSW, 2077
Country 147670 0
Australia
Phone 147670 0
+61 423264539
Fax 147670 0
Email 147670 0
Contact person for public queries
Name 147671 0
Karan Sandhu
Address 147671 0
Hornsby Hospital, Palmerston Road, Hornsby, NSW, 2077
Country 147671 0
Australia
Phone 147671 0
+61 423264539
Fax 147671 0
Email 147671 0
Contact person for scientific queries
Name 147672 0
Karan Sandhu
Address 147672 0
Hornsby Hospital, Palmerston Road, Hornsby, NSW, 2077
Country 147672 0
Australia
Phone 147672 0
+61 423264539
Fax 147672 0
Email 147672 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Individual participant data will not be shared publicly to protect participant privacy and confidentiality. All data will be stored securely and analysed in de-identified, aggregated form in accordance with HREC approval and local data governance policies.



What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Study protocolNil [email protected] PHARAOH TRIAL PROTOCOL.docx


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.